Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MODICON 28 is an oral small-molecule tablet approved in 1976 by Johnson & Johnson as an NDA product. The generic name and mechanism of action are not publicly disclosed in available data, limiting characterization of therapeutic mechanism or clinical indication.
Product is in late-stage lifecycle with limited commercial growth opportunity; team likely focused on transition planning and managing competitive pressure (30% score).
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
No linked job openings are currently available for MODICON 28, reflecting its late-lifecycle status and reduced commercial investment. Roles on this product typically focus on margin protection and transition management rather than growth.
Worked on MODICON 28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.